Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Amarilice Young

Goodwin Procter

main

Young Amarilice

Goodwin Associate Amarilice Young, from Boston, in the firm’s Business Law Department and a member of its Life Sciences group.

Amarilice Young

Areas of Practice

Professional Experience

Professional Activities

Credentials

Education

JD2017

B.A., American Studies2012

Admissions

Bars

Related Content

Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma

Abingworth to Provide Gilead Sciences Up To $210 Million in Funding

Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing

Becoming a Life Sciences Lawyer — The View From Goodwin (Chambers Associate)

Goodwin’s Life Sciences and Capital Markets Teams Advise Avadel Pharmaceuticals in Three Major Company Transactions

Bicara Therapeutics Completes Oversubscribed $108 Million Series B Financing

Nested Therapeutics Launches with $125 Million Financing

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Life Sciences